NCT06989242 · NOT YET RECRUITING
Yoga-based, Movement Therapy Device as Noninvasive Glymphatic Clearance Augmentation in Alzheimer's Disease.
This trial tests a powered device that guides users through yoga-style breathing and body movements, with the goal of improving glymphatic clearance — the brain's waste-removal system — in people who already have mild cognitive impairment or early Alzheimer's. Researchers will use brain-monitoring tools and wearables to track what happens physiologically. Phase NA means this is likely a feasibility or pilot study, not yet testing a proven therapy.
You may qualify if
- 55-85 years of age
- Current diagnostic criteria for stage 3 AD patients (AD-MCI)
- Current diagnostic criteria for stage 4 AD patients (mAD)
- Able to provide consent to be in the study
- Willing and able to participate in study activities
- Able to lay supine for 30-45 minutes
- Able to walk 20 meters
- Willing to not perform additional mind-body practices during the duration of the study
- Able to use a wearable electronic device (Smart watch)
You're excluded if
- Inability to provide informed consent
- Regular use of muscle relaxants or anti-anxiety drugs
- Any muscle or skeletal issues that would make it difficult to lie still in the supine position for the 1-hour physical therapy
- Craniospinal disorders, e.g., Chiari Malformation.
- Spinal injuries, clinically relevant disc herniation, spinal stenosis, spondylolisthesis in the sacral, lumbar, thoracic, or cervical spine, spinal bifida, Recent Spinal Surgery
- Severe osteoporosis with a risk of fracture
- History of neurological disorders such as stroke (during the last year before study start), mild brain injury within past 6 months, multiple sclerosis, presence of intracranial hemorrhage, hydrocephalus, meningitis, encephalitis, brain tumor (except of asymptomatic meningioma GI)
- Serious sleep disorders - narcolepsy
- Major or uncontrolled psychiatric illness or major depression.
- Any condition requiring the use of medication that acts on the brain such as stimulants, sedatives (hypnotics and benzodiazepines), antipsychotics, and anti-anxiety medications, (we will include patients with stable antidepressant treatment and being on mild anti-seizure medication due to polyneuropathy)
- Active infection or uncontrolled significant systemic illnesses
- Asthma, chronic obstructive pulmonary disease
- Recent hearth attack, Implantable defibrillator, poorly controlled blood pressure cardiac arrhythmia, unstable angina pectoris, or symptomatic congestive heart failure
- People at risk of blood clots or deep vein thrombosis (DVT) might want to avoid prolonged sitting in the chair
- Obesity over 135 kg (300lb)
- Smoking more than 5 cigarettes a day or drinking more than 1 alcoholic beverage a day
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-07-10